Volume Alert - AZN 72.18 Astrazeneca Plc $AZN Hit a high

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - AZN 72.18 Astrazeneca Plc $AZN Hit a high today of 72.24 Closing the day 10:30 at 72.18 -0.67 -0.92% With a day low of 71.67 and a total volume of 961,372.

AZN Recent Posts: http://investorshangout.com/AstraZeneca-PLC-AZN-50195/

AZN Astrazeneca Plc Recent Headline News

Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - 2 hrs 35 mins ago
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 205.95 (+3.33), PFE: 30.32 (-0.02), MRK: 59.53 (+0.46), AZN: 72.43 (-0.42), ABBV: 65.11 (+1.11)

Pfizer Strikes Immuno-oncology Pact with Merck After Abandoning AstraZeneca
at The Street - Mon Nov 17, 9:04AM CST
The transaction includes an upfront payment of $850 million to the German company, followed by up to $2 billion in milestone rewards.
PFE: 30.32 (-0.02), MRK: 59.53 (+0.46), AZN: 72.44 (-0.41)

Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 135.45 (+1.24), ACT: 246.54 (+2.77), F: 15.48 (+0.34), FB: 74.08 (-0.80), PFE: 30.32 (-0.02), AGN: 208.53 (+9.88), YHOO: 51.87 (+0.12), PBR: 9.35 (-0.60), DFS: 65.27 (+0.29), DTSI: 32.47 (-0.56), SPY: 204.37 (+0.13), LNKD: 222.27 (-11.62), QQQ: 102.89 (-0.33), AME: 51.15 (-0.55), MRK: 59.53 (+0.46), AOL: 46.80 (+0.76), AZN: 72.44 (-0.41), GM: 32.41 (+0.62), CVEO: 10.51 (-0.13), DD: 70.43 (-0.37)

Pfizer cuts profit outlook after Merck deal
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:06AM CST

AZN: 72.44 (-0.41), MRK: 59.53 (+0.46), PFE: 30.32 (-0.02)

7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 72.44 (-0.41), LLY: 67.26 (-0.07), ABBV: 65.12 (+1.12), GSK: 45.85 (+0.11), SNY: 47.46 (+0.78), NVS: 94.43 (+0.48)

AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Nov 16, 9:20AM CST
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether. High dividend yields may be an artificial by-product of a...
PFE: 30.32 (-0.02), AZN: 72.44 (-0.41), ABBV: 65.12 (+1.12)

AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting
Business Wire - Sun Nov 16, 8:00AM CST
AstraZeneca (NYSE: AZN) today presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with xanthine oxidase (XO) inhibitor allopurinol. The results show that approximately twice as many patients met the primary endpoint with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0 mg/dL at month 6, compared to those treated with allopurinol alone. The data was presented as a late-breaking presentation at the American College of Rheumatology (ACR) 2014 Annual Meeting in Boston, Massachusetts. Lesinurad is an investigational agent that inhibits the uric acid transporter URAT1 in the kidney, increasing uric acid excretion and thereby lowering sUA.
AZN: 72.44 (-0.41)

FibroGen Looks Healthy Heading Into IPO
Don Dion - at Seeking Alpha - Fri Nov 14, 3:30PM CST

ITMN: 73.89 (-0.02), IPF: 21.60 (unch), AZN: 72.44 (-0.41), FGEN: 23.34 (+1.34)

Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 303.53 (-1.90), ISIS: 48.98 (-0.03), AZN: 72.44 (-0.41), SNY: 47.46 (+0.78)

Cramer sees Dow Chemical in "smart, aggressive buyback"
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:38AM CST

DPS: 70.33 (+0.23), JACK: 70.05 (-1.70), FLEX: 11.00 (-0.10), VIA: 74.75 (+1.41), AZN: 72.44 (-0.41), KMB: 113.54 (+0.89), DIS: 90.42 (-0.38), M: 61.59 (-0.46), DOW: 51.13 (-0.24)

A Dividend Growth Portfolio For New Investors And Retirees: '10 Stocks' UPDATED
Dividends#1 - at Seeking Alpha - Thu Nov 13, 8:32PM CST

PM: 87.21 (+0.93), LMT: 185.61 (-0.99), KMR: 98.99 (+2.03), KMB: 113.54 (+0.89), ED: 62.52 (+0.49), AZN: 72.44 (-0.41), MCD: 95.78 (-0.43), MO: 49.04 (+0.26), O: 46.03 (+0.33), SO: 46.98 (+0.34)

AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.27 (+0.11), AZN: 72.44 (-0.41), AMGN: 159.12 (+1.44), AMAG: 34.93 (+0.93)

Cleveland Biolabs; A Diverse Play on Both Biodefense and Cancer
ACCESSWIRE - Thu Nov 13, 9:50AM CST
WHITEFISH, MT / ACCESSWIRE / November 13, 2014 / The biotechnology industry has significantly outperformed the general market for some time now. So far this year, the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) has jumped nearly 30% compared to a nearly 10% return for the S&P 500 SPDR ETF (NYSE: SPY). Investors concerned about the industry's lofty valuation may want to take a look at some smaller diversified players in the space.
SPY: 204.37 (+0.13), AZN: 72.44 (-0.41), IBB: 289.25 (+1.08), CBLI: 0.40 (unch)

BIND Therapeutics Offers Great Potential With Upcoming Catalyst
Long Term Bio - at Seeking Alpha - Thu Nov 13, 8:10AM CST

PFE: 30.32 (-0.02), MRK: 59.53 (+0.46), AZN: 72.44 (-0.41), BIND: 10.31 (+0.05)

AstraZeneca Announces Initiation of Development Program for BRILINTA (ticagrelor) Reversal Agent
Business Wire - Thu Nov 13, 6:00AM CST
AstraZeneca (NYSE: AZN) today announced that it has begun a pre-clinical development program to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor in rare emergency situations such as urgent surgery, or in the event of major bleeding. MEDI2452 is being developed by MedImmune, AstraZeneca's biologics research and development arm.
B: 37.16 (-0.14), AZN: 72.44 (-0.41)

Advaxis submits IND for HPV-associated cancers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 10:13AM CST

ADXS: 3.00 (+0.01), AZN: 72.44 (-0.41)

Look for Shares of AstraZeneca to Potentially Pullback after Yesterday's 1.35% Rise
Comtex SmarTrend(R) - Tue Nov 11, 4:14PM CST
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $73.75 to a high of $74.36. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $73.49 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 72.44 (-0.41)

AstraZeneca Set to Possibly Pullback After Yesterday's Rally of 1.35%
Comtex SmarTrend(R) - Tue Nov 11, 4:14PM CST
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $73.75 to a high of $74.36. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $73.49 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 72.44 (-0.41)

Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST

CANF: 2.34 (-0.07), JNJ: 108.27 (+0.11), IDRA: 2.36 (-0.09), DERM: 16.34 (+0.29), MRK: 59.53 (+0.46), PFE: 30.32 (-0.02), AZN: 72.44 (-0.41), AMGN: 159.12 (+1.44), GSK: 45.85 (+0.11), HSP: 58.33 (+0.05), NVS: 94.43 (+0.48), CELG: 104.39 (+0.34)

Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
PR Newswire - Tue Nov 11, 3:01PM CST
Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12. Brodalumab was shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index (PASI 100). When compared with placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75 percent improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75). A significantly greater proportion of patients treated with brodalumab also achieved clear or almost clear skin at week 12 compared with placebo, according to the static Physician Global Assessment (sPGA 0 or 1). All key secondary endpoints comparing brodalumab with Stelara and placebo were also met.
AZN: 72.44 (-0.41), AMGN: 159.12 (+1.44)

AstraZeneca PLC (AZN) Stock Research Links

AZN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 18

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 200

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 95

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 29

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 17

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 136

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 177

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 283

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 62

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Birkenstock Holding Q1 Earnings Highlights and Insights

Updated Category News Views 174

Birkenstock Holding Q1 Earnings Overview Birkenstock Holding (NYSE: BIRK) recently shared insights from its first quarter earnings report, showcasing the company’s financial performance and strategic advancements. This update reveals not only earnings results but also highlights on how the company is faring in a competitive market. Earnings Results The company's...

Continue Reading
Kinepolis Group Announces Upcoming Dividend Payment Details

Updated Category News Views 228

Kinepolis Group Dividend Announcement The Kinepolis Group NV is pleased to inform its shareholders of an upcoming dividend payout, a noteworthy event for investors looking to maximize their returns. Dividend Payment Details The company has officially announced a gross dividend of €0.55 per share. After the deduction of the standard 30% withholding tax, shareholders will...

Continue Reading
Celebrating Success: Medical Solutions Recognized in Regionals

Updated Category News Views 144

Celebrating Growth and Achievement for Medical Solutions Recognized for three consecutive years as a leader in healthcare workforce solutions Medical Solutions, a prominent name in healthcare workforce solutions, has been honored once again for its exceptional growth trajectory, being listed among the Midwest's fastest-growing companies. This prestigious recognition marks...

Continue Reading
Unlocking the Future: SEALSQ's MS6003 Secure Element Launch

Updated Category News Views 208

Revolutionizing Secure Authentication with MS6003 SEALSQ Corp (NASDAQ: LAES), a leader in semiconductor innovation, has recently announced a significant addition to its product portfolio: the MS6003 secure element chip. This state-of-the-art chip is equipped with a preloaded FIDO2 application, marking a pivotal step towards enhancing passwordless authentication in an era...

Continue Reading
Navigating Income with High-Dividend Utility Stocks Today

Updated Category News Views 114

Staying Afloat with Utility Stocks In challenging market conditions, many investors search for stability. This leads them to utility stocks, particularly those offering attractive dividend yields. Utilities often provide steady cash flows and dividends, making them appealing for income-seeking investors. Dividend Opportunities in Utilities Sector As the market shifts,...

Continue Reading